Infinitum Asset Management LLC Purchases Shares of 155,529 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Infinitum Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 155,529 shares of the company's stock, valued at approximately $1,218,000. Y-mAbs Therapeutics accounts for 0.6% of Infinitum Asset Management LLC's holdings, making the stock its 16th biggest holding. Infinitum Asset Management LLC owned approximately 0.35% of Y-mAbs Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Principal Financial Group Inc. lifted its position in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after buying an additional 1,903 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Y-mAbs Therapeutics by 12.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock worth $179,000 after buying an additional 2,545 shares during the period. JPMorgan Chase & Co. increased its position in Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock valued at $399,000 after acquiring an additional 2,854 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock valued at $139,000 after acquiring an additional 4,163 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Y-mAbs Therapeutics by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock valued at $2,228,000 after acquiring an additional 4,963 shares during the period. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Price Performance

YMAB traded down $0.04 during trading on Friday, reaching $4.71. 253,129 shares of the company's stock were exchanged, compared to its average volume of 310,963. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.55 and a 1 year high of $16.11. The stock has a market capitalization of $213.29 million, a P/E ratio of -8.72 and a beta of 0.53. The company's fifty day simple moving average is $4.37 and its 200-day simple moving average is $6.38.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.10. The company had revenue of $20.90 million during the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. Equities analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Insider Activity

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares of the company's stock, valued at $1,060,230.83. This trade represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 22.50% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on YMAB. HC Wainwright dropped their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target for the company. in a research note on Tuesday, April 22nd. Truist Financial reduced their target price on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Oppenheimer cut their price target on shares of Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.60.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.